Immunovant
Lawrence Marotta, CPA, serves as the Senior Director of SEC Reporting, Technical Accounting & Tax at Immunovant and previously held the position of Executive Director of Finance/Controller in the Greater New York Area. With extensive experience in financial leadership, Lawrence Marotta specializes in regulatory compliance and technical accounting matters.
This person is not in any teams
This person is not in any offices
Immunovant
6 followers
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.